Rheumatology International

, Volume 32, Issue 1, pp 145–150 | Cite as

Theory-based analysis of anti-inflammatory effect of infliximab on Crohn’s disease and rheumatoid arthritis

  • Koji Kimura
  • Risa Takayanagi
  • Haruko Yokoyama
  • Yasuhiko Yamada
Original Article


In Japan, the recommended dosage regimens of infliximab (IFX) for treatment of rheumatoid arthritis (RA) and Crohn’s disease (CD) are different. However, the differences have not been analyzed theoretically. In a previous study, we constructed a pharmacokinetic–pharmacodynamic model to investigate the effects of IFX for CD and found it useful to establish a rational dosage regimen of IFX for individual patients with CD. In the present study, we investigated whether the theory-based model could be used for cases of RA and also used it to evaluate the validity of the dosage regimen. The results obtained with our model were in good agreement with observed tender joint count (TJC) ratio data, which was considered to show the validity of our analysis. Thus, we concluded that the model could be used for patients with RA. Furthermore, a second administration of IFX given 2 weeks after the first infusion was important to achieve remission in the early stage of RA. We also compared the estimated pharmacodynamic parameters of RA with those of CD. The elimination rate constant of inflammation in RA was greater than that in CD, suggesting that the recovery from inflammation in RA is faster than that in CD, and indicating a reason for the difference in dosage between RA and CD. In conclusion, use of our model in light of the individual quantitative factor of tumor necrosis factor (TNF)-α allows establishment of IFX dosage regimens for individual patients.


Infliximab Crohn’s disease Rheumatoid arthritis Pharmacokinetics 



We are grateful to Dr. Takeshi Ozeki for advising this work.


  1. 1.
    Kaneko M, Tomita T, Nakase T, Ohsawa Y, Seki H, Takeuchi E, Takano H, Shi K, Takahi K, Kominami E et al (2001) Expression of proteinases and inflammatory cytokines in subchondral bone regions in the destructive joint of rheumatoid arthritis. Rheumatology (Oxford) 40:247–255CrossRefGoogle Scholar
  2. 2.
    Feldmann M, Brennan FM, Maini RN (1996) Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14:397–440. doi: 10.1146/annurev.immunol.14.1.397 PubMedCrossRefGoogle Scholar
  3. 3.
    Imura Y (2008) Wakariyasui Naikagaku. bunkoudou, TokyoGoogle Scholar
  4. 4.
    Eigler A, Sinha B, Hartmann G, Endres S (1997) Taming TNF: strategies to restrain this proinflammatory cytokine. Immunol Today 18:487–492PubMedCrossRefGoogle Scholar
  5. 5.
    Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT (1992) Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 339:89–91PubMedCrossRefGoogle Scholar
  6. 6.
    Garnett WR, Yunker N (2001) Treatment of Crohn’s disease with infliximab. Am J Health Syst Pharm 58:307–316 quiz 317–309PubMedGoogle Scholar
  7. 7.
    Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, Wagner C (2002) Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 301:418–426PubMedCrossRefGoogle Scholar
  8. 8.
    Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J (1995) Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 7:251–259. doi: 10.1006/cyto.1995.0029 PubMedCrossRefGoogle Scholar
  9. 9.
    Siegel SA, Shealy DJ, Nakada MT, Le J, Woulfe DS, Probert L, Kollias G, Ghrayeb J, Vilcek J, Daddona PE (1995) The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine 7:15–25. doi: 10.1006/cyto.1995.1003 PubMedCrossRefGoogle Scholar
  10. 10.
    REMICADE for I.V. infusion100 (2007) Product InformationGoogle Scholar
  11. 11.
    Furuya Y, Ozeki T, Takayanagi R, Yokoyama H, Okuyama K, Yamada Y (2007) Theory based analysis of anti-inflammatory effect of infliximab on Crohn’s disease. Drug Metab Pharmacokinet 22:20–25PubMedCrossRefGoogle Scholar
  12. 12.
    Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S et al (1997) A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385:729–733. doi: 10.1038/385729a0 PubMedCrossRefGoogle Scholar
  13. 13.
    Cornillie F, Shealy D, D’Haens G, Geboes K, Van Assche G, Ceuppens J, Wagner C, Schaible T, Plevy SE, Targan SR et al (2001) Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn’s disease. Aliment Pharmacol Ther 15:463–473PubMedCrossRefGoogle Scholar
  14. 14.
    Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W et al (2002) Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 359:1541–1549. doi: 10.1016/S0140-6736(02)08512-4 PubMedCrossRefGoogle Scholar
  15. 15.
    Couriel DR, Hicks K, Giralt S, Champlin RE (2000) Role of tumor necrosis factor-alpha inhibition with inflixiMAB in cancer therapy and hematopoietic stem cell transplantation. Curr Opin Oncol 12:582–587PubMedCrossRefGoogle Scholar
  16. 16.
    Robak T, Gladalska A, Stepien H (1998) The tumour necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis. Eur Cytokine Netw 9:145–154PubMedGoogle Scholar
  17. 17.
    Blick M, Sherwin SA, Rosenblum M, Gutterman J (1987) Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res 47:2986–2989PubMedGoogle Scholar
  18. 18.
    Bocci V (1991) Interleukins. Clinical pharmacokinetics and practical implications. Clin Pharmacokinet 21:274–284PubMedCrossRefGoogle Scholar
  19. 19.
    Furusawa SIJ (1998) Laboratory hematology, 3rd edn. Igaku-Shoin, TokyoGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Koji Kimura
    • 1
  • Risa Takayanagi
    • 1
  • Haruko Yokoyama
    • 1
  • Yasuhiko Yamada
    • 1
  1. 1.Department of Clinical Evaluation of Drug Efficacy, School of PharmacyTokyo University of Pharmacy and Life SciencesHachiojiJapan

Personalised recommendations